Floatz logo

Ftc-146

Spinal Cord Disorder

Stanford UniversitySmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Spinal Cord Disorder cohort.

Asset / SponsorPhaseRating
Ziconotide
Aaron Boster
Phase 4BB

Same molecule, other indications

Ftc-146 is also rated in:

radiculopathyDormant
CC
Indicative · Phase 1
43 / 100
View asset →
vertebral column disorderDormant
CC
Indicative · Phase 1
43 / 100
View asset →
complex regional pain syndromeDormant
CC
Indicative · Early Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →